Diabetic retinopathy
Diabetic Retinopathy (DR) is the leading cause of blindness among working-aged adults. As DR progresses, it affects eyesight: blurred vision, seeing double, spots or floaters in the field of vision. Current treatments are only indicated in advanced stages of the disease, and have limited effectiveness. The early stages of DR usually have no symptoms and the disease progresses unnoticed with no available treatment. Therefore we are facing an unmet clinical need.
26M
patients worldwide
8M
patients with early DR
1%
of all cases of blindness in EU and USA
In 2019
Retina of a healthy person
~5 years
NO TREATMENT EXISTS FOR EARLY STAGES OF DR
Retina of a person with DR
Solution and value proposition
Retinset has developed a unique formulation that enables the drug to effectively reach the retina. Our eye drops prevent and regress early stage DR avoiding invasive surgical treatment.
DR is detected
Eye drops prevent and regress early stage DR
This unique formulation enables the drug to effectively reach the retina
Dual effect neuroprotection AND microvascular protection
Invasive surgical treatment is avoided
BSL01 is a topical ophthalmic formulation (eye drops) that enables the drug to effectively reach the retina. BSL01 stops the progression of Diabetic Retinopathy in its early stages, and also is able to revert its effects.
Formulation platform
Development of innovative formulation strategies for ophthalmic drug delivery. Eco-friendly formulations. Patent protected.
